---
title: "practice guidelines treatment prevention hiv infection"
year: 2024
month: 01
journal: "American Family Physician"
volume: "109-110"
issue: "01"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2024-01-practice-guidelines-treatment-prevention-hiv-infection.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# practice guidelines treatment prevention hiv infection

                                               Practice Guidelines
     Treatment and Prevention of HIV Infection:​
     Recommendations From the International
            Antiviral Society-USA Panel
                                                                                 immediately with negative point-of-care HIV
               Key Points for Practice
                                                                                 testing or negative testing within seven days.
               • For HIV PrEP, options include daily or episodic
                                                                                 Regular laboratory testing is recommended for
                  emtricitabine/tenofovir disoproxil fumarate
                  (Truvada) or daily emtricitabine/tenofovir                     patients taking PrEP (Table 1).
                  alafenamide (Descovy) and injectable cabote-                     Multiple PrEP dosing regimens are effective.
                  gravir (Apretude) every four to eight weeks.                   Emtricitabine/tenofovir disoproxil fumarate
               • Rapid treatment initiation after HIV diagnosis                 (Truvada) is effective when taken daily and for
                  improves outcomes; starting within seven days                  on-demand episodic use in those who do not
                  is recommended in patients without opportu-                    use injection drugs, with a double dose two to 24
                  nistic infections and within 14 days in patients
                  with most opportunistic infections.
                                                                                 hours before sexual activity and single doses daily
                                                                                 until 48 hours after sexual activity. Emtricitabine/
               • Most treatment failures are due to missed
                  doses, so simplifying treatment regimens can                   tenofovir alafenamide (Descovy) is taken daily
                  be effective for patients with and without                     and is safer for use in chronic kidney disease and
                  virologic suppression.                                         osteopenia but leads to more weight gain. Long-
                                                 From the AFP Editors            acting injectable cabotegravir (Apretude) is also


            Four decades after the initial HIV case was                               G-TRUST SCORECARD
            reported, strategies for treating and preventing
            the disease continue to advance. In the United                            Score      Criteria
            States, the HIV epidemic continues to dispropor-
                                                                                       Yes       Focus on patient-oriented outcomes
            tionately affect people who are Black or Hispanic,
            men who have sex with men, people who are                                  Yes       Clear and actionable recommendations
            transgender, and individuals who use illicit drugs.
                                                                                       Yes       Relevant patient populations and conditions
            HIV is increasingly diagnosed in older adults, and
            one-fourth of HIV-positive people will be older                            Yes       Based on systematic review
            than 65 years by 2030.
                                                                                       Yes       Evidence graded by quality
            HIV Prevention                                                                       Separate evidence review or analyst in guideline
                                                                                       Yes
            Condom use remains the foundation of HIV                                             team
            prevention. Preexposure prophylaxis (PrEP)
                                                                                                 Chair and majority free of conflicts of interest
            is proven to reduce incidence and should be                                 No
                                                                                                 (potential conflicts for more than half)
            discussed with all sexually active adults and
            adolescents, especially cisgender men and trans-                                     Development group includes mostly relevant
                                                                                        No       specialties, patients, and payers (no payers or
            gender individuals who have sex with men, peo-
                                                                                                 patients)
            ple with a recent sexually transmitted infection,
            and those with substance use disorder or who                                         Overall—useful
            inject nonprescription drugs. PrEP can be started                         Note:​ See related editorial, Where Clinical Practice Guidelines Go
                                                                                      Wrong, at https://​w ww.aafp.org/afp/gtrust.html.

                CME This clinical content conforms to AAFP cri-                       G-TRUST = guideline trustworthiness, relevance, and utility scor-
                                                                                      ing tool.
               teria for CME. See CME Quiz on page 13.
                                                                                      Copyright © 2017 Allen F. Shaughnessy, PharmD, MMedEd, and
               Author disclosure:​ No relevant financial
                                                                                      Lisa Cosgrove, PhD. Used with permission.
               relationships.


 Downloaded
January 2024from the American
              ◆ Volume        Family Physician
                       109, Number    1        website at www.aafp.org/afp.        © 2024 American Academy of American
                                                                            Copyright
                                                             www.aafp.org/afp                                              Family
                                                                                                               Family Physicians.     the private, 93A
                                                                                                                                  ForPhysician     non-
commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                                 PRACTICE GUIDELINES


                                                                                 effective; injections should start every four weeks and can be
   TABLE 1                                                                       extended to eight weeks apart. Oral PrEP regimens are rec-
                                                                                 ommended after cabotegravir (Apretude) is discontinued.
   Recommended Laboratory Analyses                                                  Postexposure prophylaxis with 28 days of a three-drug
   for HIV Prophylaxis and Treatment                                             regimen of bictegravir/emtricitabine/tenofovir alafenam-
   Timing              Testing                                                   ide (Biktarvy); or dolutegravir (Tivicay) plus emtricitabine/
                                                                                 tenofovir disoproxil fumarate (Truvada) or emtricitabine/
   Preexposure         Every three to four months                                tenofovir alafenamide (Descovy) or lamivudine/tenofovir
   prophylaxis           HIV fourth-generation testing;​results                  disoproxil fumarate (Temixys) is recommended within 72
                         are not needed before cabotegravir                      hours of exposure to blood or genital secretions from a per-
                         (Apretude) injections
                                                                                 son who is suspected to be HIV positive. For transgender
                         Gonorrhea, chlamydia, and syphilis
                                                                                 individuals who have sex with men who are at high risk,
                         testing*
                                                                                 adding a single 200-mg dose of doxycycline after intercourse
                         Pregnancy testing
                                                                                 without a condom should be considered to prevent gonor-
                         Creatinine level, unless taking cabote-
                                                                                 rhea, chlamydia, and syphilis.
                         gravir (Apretude)
                         HIV RNA level if taking cabotegravir                    Initiation of Antiretroviral Therapy
                         (Apretude)
                                                                                 TIMING
                       Annually
                                                                                 Rapid initiation of treatment after diagnosis of HIV
                         Hepatitis C antibody testing
                                                                                 improves life expectancy and reduces HIV transmission
   Initial HIV         HIV RNA level                                             to others. Initiation within seven days of diagnosis is rec-
   diagnosis           CD4 cell count                                            ommended for rapid viral suppression. Barriers such
   and starting
   treatment           HIV RT-pro genotype testing                               as transportation, housing instability, racism, cost, and
                       STI and viral hepatitis screening                         stigma should be addressed through case management and
                       Cryptococcal antigen testing if CD4 cell                  peer navigation.
                       count < 100 cells per µL                                     If there is evidence of an opportunistic infection at the
                       HIV integrase genotype testing if taking                  time of diagnosis, antiretroviral therapy can usually be
                       cabotegravir (Apretude) preexposure pro-                  started within two weeks of starting treatment of the infec-
                       phylaxis or if partner has failing regimen                tion. Patients with active tuberculosis can start antiretro-
                       with integrase strand transfer inhibitor
                                                                                 viral therapy within two weeks of starting antibacterial
                       Human leukocyte antigen B*5701 testing                    treatment. When cryptococcal meningitis is diagnosed with
                       if starting abacavir (Ziagen)
                                                                                 HIV, antiretroviral therapy can be started two to four weeks
   During              HIV RNA level every three months until                    after starting antifungal therapy. HIV treatment can be
   treatment           suppressed, then every six months                         started immediately with cancer therapy.
                       CD4 cell count every six months until
                       250 cells per µL for one year, then stop if               MEDICATIONS
                       RNA level is suppressed
                                                                                 Initial regimens for HIV should include an integrase
                       STI and viral hepatitis screening
                                                                                 strand transfer inhibitor: dolutegravir (Tivicay) plus
                       HIV RT-pro genotype testing if switching
                       to injectable medications

   Virologic           HIV RNA level
   failure             CD4 cell count                                                TABLE 2
                       HIV RT-pro genotype testing
                                                                                     Recommended Initial Medication Regimens
                       STI and viral hepatitis screening
                                                                                     for Most Adults Diagnosed With HIV
                       HIV integrase genotype testing if failing
                       regimen includes an integrase strand                          Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy)
                       transfer inhibitor
                                                                                     Dolutegravir (Tivicay) plus emtricitabine/tenofovir
                       Viral trophism testing if switching to mar-                   disoproxil fumarate (Truvada) or emtricitabine/tenofovir
                       aviroc (Selzentry)                                            alafenamide (Descovy) or lamivudine/tenofovir disoproxil
                                                                                     fumarate (Temixys)
   STI = sexually transmitted infection.
   *—Test all sites used for sexual activity (i.e., vaginal, rectal, urethral        ​If HIV RNA < 500,000 copies per mL and hepatitis B coin-
   [via urine testing], and pharyngeal).                                              fection is not present, dolutegravir/lamuvidine (Dovato)



93B American Family Physician                                        www.aafp.org/afp                        Volume 109, Number 1 ◆ January 2024
                                                PRACTICE GUIDELINES


a tenofovir combination or bictegravir/emtricitabine/           resistance testing results should be assessed. With nega-
tenofovir alafenamide (Biktarvy; Table 2).                      tive resistance testing results, tools to improve adherence,
  If HIV is diagnosed in patients taking PrEP, treatment        including simpler regimens, can be offered.
varies based on PrEP medication. If tenofovir was used for
PrEP, a regimen with dolutegravir (Tivicay) plus a tenofo-      Primary Care
vir combination is recommended (Table 2). Antiretroviral        Although weight gain is an adverse effect of several HIV
therapy resistance testing should be performed when med-        medications, switching medications does not seem to reduce
ications are started. If cabotegravir (Apretude) was used for   weight gain. HIV and its treatment increase cardiac risk, and
PrEP, wait for integrase strand transfer inhibitor genotyping   at least annual evaluation is recommended. Routine age- and
or start darunavir (Prezista), tenofovir, and emtricitabine     risk-based screening is recommended for people with HIV,
or lamivudine.                                                  including regular sexually transmitted infection screening
  For HIV diagnosed during pregnancy, dolutegravir (Tiv-        at exposed mucosal sites and screening for cancers, tubercu-
icay), emtricitabine/tenofovir alafenamide (Descovy), and       losis, and viral hepatitis.
lamivudine are the primary medication regimen recom-               Substance use disorders disproportionately affect people
mended. Tenofovir disoproxil fumarate is an alternative to      with HIV, and medication treatment improves HIV treat-
tenofovir alafenamide.                                          ment outcomes.

MONITORING                                                       Editor’s Note:​ This guideline contains an updated succinct
Monitoring during treatment includes HIV RNA levels and          evidence review of HIV prevention and treatment. Although
CD4 cell counts until proven stable (Table 1).                   most recommendations match guidance from the Centers for
                                                                 Disease Control and Prevention, these guidelines include more
                                                                 recent evidence.—Michael J. Arnold, MD, Contributing Editor
Switching Antiretroviral Medications
Before switching medications, treatment history, medica-        The views expressed are those of the author and do not nec-
tions and tolerance, reproductive plans, insurance coverage,    essarily reflect the official policy or position of the Uniformed
and resistance testing results should be reviewed. More fre-    Services University of the Health Sciences, U.S. Navy, U.S.
quent laboratory monitoring is recommended after switch-        Department of Defense, or U.S. government.
ing medications.                                                Guideline source:​ International Antiviral Society-USA Panel
   For patients with viral suppression and no drug resis-       Published source:​ Gandhi RT, Bedimo R, Hoy JF, et al. Antiret-
                                                                roviral drugs for treatment and prevention of HIV infection in
tance, other regimens are generally safe, including the
                                                                adults:​2022 recommendations of the International Antiviral
two-drug regimens of dolutegravir/lamivudine (Dovato)           Society-USA Panel. JAMA. 2023;​329(1):​63-84.
or dolutegravir/rilpivirine (Juluca). Cabotegravir (Apre-       Available at:​ https://​jamanetwork.com/journals/jama/fullarticle/​
tude) and rilpivirine (Edurant) injections are convenient       2799240
but have up to a 2% risk of resistance that can complicate
future treatment.                                               Michael J. Arnold, MD, FAAFP
                                                                Naval Undersea Medical Institute
   When virologic failure occurs with HIV RNA levels            Groton, Conn.
greater than 200 copies per mL, medication adherence and        michael.arnold@​usuhs.edu ■




January 2024 ◆ Volume 109, Number 1                www.aafp.org/afp                               American Family Physician 93C
